Sarah Ackroyd to Cost-Benefit Analysis
This is a "connection" page, showing publications Sarah Ackroyd has written about Cost-Benefit Analysis.
Connection Strength
0.728
-
Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. Gynecol Oncol. 2021 08; 162(2):249-255.
Score: 0.632
-
Effectiveness of diabetes interventions in the patient-centered medical home. Curr Diab Rep. 2014 Mar; 14(3):471.
Score: 0.096